TaiGen Biopharmaceuticals Holdings Limited
4157.TWO
Price:
$11.15
Market Cap:
$7.94B
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was fou...[Read more]
Industry
Biotechnology
IPO Date
2013-08-30
Stock Exchange
TWO
Ticker
4157.TWO
PE Ratio
[-44.60]
ROE
[-22.99%]
Current Ratio
[12.81]
Dividend Yield
[0%]
Enterprise Value
[7.99B]
Dividend History
The ROE as of December 2025 (TTM) for TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) is -22.99%
According to TaiGen Biopharmaceuticals Holdings Limited’s latest financial reports and current stock price. The company's current ROE is -22.99%. This represents a change of 290.53% compared to the average of -5.89% of the last 4 quarters.
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) Historical ROE (quarterly & annually)
How has 4157.TWO ROE performed in the past?
The mean historical ROE of TaiGen Biopharmaceuticals Holdings Limited over the last ten years is -19.13%. The current -22.99% ROE has changed 20.17% with respect to the historical average. Over the past ten years (40 quarters), 4157.TWO's ROE was at its highest in in the June 2021 quarter at 72.38%. The ROE was at its lowest in in the December 2020 quarter at -29.46%.
Average
-19.13%
Median
-27.92%
Minimum
-93.52%
Maximum
61.87%
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) ROE by Quarter and Year
Discovering the peaks and valleys of TaiGen Biopharmaceuticals Holdings Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 152.40%
Maximum Annual ROE = 61.87%
Minimum Annual Increase = -241.58%
Minimum Annual ROE = -93.52%
| Year | ROE | Change |
|---|---|---|
| 2024 | -3.56% | -129.17% |
| 2023 | 12.22% | -149.98% |
| 2022 | -24.45% | -139.52% |
| 2021 | 61.87% | -167.58% |
| 2020 | -91.55% | 152.40% |
| 2019 | -36.27% | 15.55% |
| 2018 | -31.39% | -159.91% |
| 2017 | 52.40% | -241.58% |
| 2016 | -37.01% | -60.43% |
| 2015 | -93.52% | 97.40% |
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) Average ROE
How has 4157.TWO ROE performed in the past?
The current ROE of TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-5.26%
5-year avg
-9.10%
10-year avg
-19.13%
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) ROE vs. Peers
How is 4157.TWO’s ROE compared to its peers?
TaiGen Biopharmaceuticals Holdings Limited’s ROE is greater than Pharmosa Biopharm Inc. (-15.24%), greater than OBI Pharma, Inc. (-79.60%), greater than Mycenax Biotech Inc. (-25.50%), greater than CHO Pharma, Inc. (-8.57%), less than Sinphar Pharmaceutical Co.,Ltd. (9.51%), greater than Adimmune Corporation (-4.48%), greater than BioGend Therapeutics Co., Ltd. (-15.67%), less than Panion & Bf Biotech Inc. (6.83%), less than Savior Lifetec Corporation (12.67%), less than Locus Cell Co., Ltd. (0%),
| Company | ROE | Market cap |
|---|---|---|
| -15.24% | $6.92B | |
| -79.60% | $7.59B | |
| -25.50% | $6.76B | |
| -8.57% | $6.42B | |
| 9.51% | $5.83B | |
| -4.48% | $8.14B | |
| -15.67% | $4.75B | |
| 6.83% | $5.72B | |
| 12.67% | $5.65B | |
| 0% | $5.77B |
Build a custom stock screener for TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TaiGen Biopharmaceuticals Holdings Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) and other stocks custom spreadsheet templates
The easiest way to analyze a company like TaiGen Biopharmaceuticals Holdings Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is TaiGen Biopharmaceuticals Holdings Limited's ROE?
How is the ROE calculated for TaiGen Biopharmaceuticals Holdings Limited (4157.TWO)?
What is the highest ROE for TaiGen Biopharmaceuticals Holdings Limited (4157.TWO)?
What is the 3-year average ROE for TaiGen Biopharmaceuticals Holdings Limited (4157.TWO)?
What is the 5-year average ROE for TaiGen Biopharmaceuticals Holdings Limited (4157.TWO)?
How does the current ROE for TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) compare to its historical average?